Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
11/14/17Aerpio Pharmaceuticals Announces Appointment of Michael Rogers as Chief Financial Officer
CINCINNATI--(BUSINESS WIRE)--Nov. 14, 2017-- Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, announced today that Michael Rogers has been appointed Chief Financial Officer effective as of November 15, 2017. Mr. Rogers has more than 25 years of experience in the biopharmaceutical industry, serving as Chief Financial Officer (CFO) of five publicly-tra... 
Printer Friendly Version
11/13/17Aerpio Reports Third Quarter 2017 Financial Results
Strengthened Senior Leadership Team with the Appointment of Stephen Hoffman, M.D., Ph.D., as Chief Executive Officer Effective December 1, 2017 TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track CINCINNATI--(BUSINESS WIRE)--Nov. 13, 2017-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported... 
Printer Friendly Version
10/10/17Aerpio Pharmaceuticals Announces Appointment of Stephen Hoffman, M.D., Ph.D., as Chief Executive Officer and to the Board of Directors and the Transition of Joseph H. Gardner, Ph.D., to President and Founder
CINCINNATI--(BUSINESS WIRE)--Oct. 10, 2017-- Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for diabetic retinopathy and other ocular diseases, announced today that Stephen Hoffman, M.D., Ph.D., has been appointed Chief Executive Officer, effective as of December 1, 2017, and is expected to be appointed to its board of directors as a Class I director in connection with the commenceme... 
Printer Friendly Version
08/14/17Aerpio Reports Second Quarter 2017 Financial Results
Commenced Trading on the OTCQB® Market Continue to Dose Patients in the TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy CINCINNATI--(BUSINESS WIRE)--Aug. 14, 2017-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the second quarter ended June 30, 2017. Sec... 
Printer Friendly Version
08/08/17Aerpio Pharmaceuticals Commences Trading on the OTCQB® Market
... 
Printer Friendly Version
06/29/17Aerpio Announces Initiation of Patient Dosing in the TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic Retinopathy
... 
Printer Friendly Version
03/29/17Aerpio Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
... 
Printer Friendly Version
03/16/17Aerpio Pharmaceuticals Raises $40 Million
... 
Printer Friendly Version
03/15/17Aerpio Reports First Quarter 2017 Financial Results
... 
Printer Friendly Version
03/08/17Aerpio Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference
... 
Printer Friendly Version